Complementing the Cancer-Immunity Cycle

Reactivation of cytotoxic CD8(+) T-cell responses has set a new direction for cancer immunotherapy. Neutralizing antibodies targeting immune checkpoint programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been particularly successful for tumor types with limited therapeutic options such...

Descripción completa

Detalles Bibliográficos
Autores principales: Pio, Ruben, Ajona, Daniel, Ortiz-Espinosa, Sergio, Mantovani, Alberto, Lambris, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473060/
https://www.ncbi.nlm.nih.gov/pubmed/31031765
http://dx.doi.org/10.3389/fimmu.2019.00774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473060/
https://www.ncbi.nlm.nih.gov/pubmed/31031765
http://dx.doi.org/10.3389/fimmu.2019.00774

Ejemplares similares